Finasteride Compounding Legal Status: FDA Approval, Label Details, and Regulatory History
A clinical review of finasteride's FDA approval history, current compounding legal status, official label warnings, and post-market safety surveillance data.
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.

Showing 8 of 8 clinical reviews.
A clinical review of finasteride's FDA approval history, current compounding legal status, official label warnings, and post-market safety surveillance data.
A detailed comparison of how the FDA and EMA regulate finasteride, covering approval timelines, label warnings, post-market surveillance, and what the divergence means for prescribers and patients.
A clinical review of finasteride safety signals in the FDA Adverse Event Reporting System (FAERS), including sexual dysfunction, depression, and suicidality reports that prompted label revisions.
A complete regulatory timeline of finasteride's FDA approval history, covering Proscar (1992), Propecia (1997), generic entry, label changes, and current safety requirements.
A comprehensive review of finasteride's regulatory approvals worldwide, including FDA history, EMA authorization, label updates, post-market safety signals, and current prescribing requirements across major markets.
A complete breakdown of every FDA label change to finasteride (Propecia, Proscar) from 2020 through 2026, including post-market safety signals, prescriber obligations, and what the updated warnings mean for patients on TRT or hair-loss therapy.
A comprehensive review of finasteride's FDA approval timeline, patent disputes, generic entry, label evolution, post-market safety signals, and ongoing litigation, with primary-source citations throughout.
A full regulatory history of finasteride, including FDA approval dates, Black Box label changes, post-market surveillance findings, and next-generation 5-ARI alternatives in development.